Back to Archived News
VIA Pharmaceuticals Announces Grant of New Patent Rights - Phosphodiesterase Inhibitors
Monday, August 06, 2007
San Francisco, CA -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of vascular inflammation, announced today that the United States Patent and Trademark Office had granted its patent entitled "Cyclic Nucleotide Phosphodiesterase Inhibitors, Preparation and Uses Thereof." The patent has also been granted in New Zealand, South Africa and India and is pending in other countries.
The novel compounds covered by VIA’s latest patent exhibit phoshodiesterase (PDE) inhibition, principally PDE4 inhibition, and may be active in certain PDE subtypes. VIA will evaluate these compounds in its pre-clinical research program, and will work with its collaborators to test their utility in the treatment of cardiovascular inflammation and other inflammatory conditions.
"Given the potential for PDE4 inhibition as a means of treating other diseases mediated by inflammation, we believe it is important for us to initiate a broad development program from the outset" stated Lawrence K. Cohen, VIA’s CEO and president. "The identification of compounds with broad anti-inflammatory properties could provide VIA with interesting partnering and development opportunities," added Brendan P. Rae, VIA’s vice president of Licensing and Business Development.
"Our intellectual property strategy continues to provide strong support for the research and development objectives of the company" commented Cohen. "This is the latest example of VIA’s ability to implement this strategy."
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target inflammation in the blood vessel wall, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. VIA's lead drug candidate, VIA-2291, is in two concurrent Phase II clinical studies in patients with cardiovascular disease. VIA is headquartered in San Francisco, CA. For more information, visit: www.viapharmaceuticals.com.
Back to Archived News